A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

BackgroundFor unresectable stage III non-small cell lung cancer (NSCLC), concurrent chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC harboring driver-gene mutations benefit from Tyrosine Kinase Inhibitors (TKIs) Therapy. In a real-world setting, there is room for ex...

Full description

Bibliographic Details
Main Authors: Ranpu Wu, Shaorong Yu, Jinjun Ye, Yimin Wang, Zhiting Zhao, Hongbing Liu, Yong Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
NSCLC
stage III unresectable
EGFR
TKI
surgery
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.692703/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.692703/full

Similar Items